The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.
The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V52110 | Etesevimab (CB 6; JS016) | 2423948-94-9 | Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody (mAb). |
|
V52097 | FASN-IN-4 tosylate | 2095432-57-6 | FASN-IN-4 tosylate is a highly effective fatty acid synthase FASN inhibitor (antagonist) with IC50 of 10 nM (WO2012064642A1, compound 29). |
|
V83702 | FGA145 | ||
|
V52632 | Fluphenazine-d8 | 1323633-98-2 | Fluphenazine-d8 is a deuterated marker of Fluphenazine. |
|
V28295 | FOY-251 HCl | FOY 251 HCl is a Camostat metabolite withanti-proteolytic activity, and acts as a proteinase inhibitor. | |
|
V54399 | Gallinamide A | 1208232-55-6 | Gallinamide A is a potent inhibitor of cathepsin L with IC50 of 17.6 pM. |
|
V54393 | Garcinone B | 76996-28-6 | Garcinone B is a xanthone analogue, a naturally occurring compound that can be extracted from the peel of mangosteen. |
|
V86212 | GC-78-HCl | 3022242-53-8 | |
|
V54420 | Gimsilumab (MORAb-022) | 1648796-29-5 | Gimsilumab is a humanized anti-GM-CSF monoclonal antibody (mAb). |
|
V52044 | GRL-0496 | 1087243-14-8 | GRL-0496 is a potent clopyridine-derived SARS-CoV 3CLpro inhibitor (antagonist) with IC50 of 30 nM. |
|
V52043 | GRL-1720 | 2835511-03-8 | GRL-1720 is a potent SARS-CoV-2 Mpro inhibitor (antagonist) with EC50 of 15 µM. |
|
V76958 | GRL-1720 TFA | GRL-1720 TFA is a potent inhibitor of SARS-CoV-2 Mpro with EC50 of 15 μM. | |
|
V83554 | GRL-190-21 | 2755957-14-1 | |
|
V53038 | GS-621763 | 2647442-13-3 | GS-621763 is an orally bioavailable precursor of GS-441524 that displays activity against SARS-CoV-2 virus in mice. |
|
V54382 | Guanosine triphosphate (GTP) | 86-01-1 | Guanosine triphosphate is a natural nucleotide. |
|
V84436 | hACE2/SP-IN-1 | ||
|
V52004 | HCoV-229E-IN-1 | 2639757-13-2 | HCoV-229E-IN-1 is a potent inhibitor of HCoV-229E replication, with EC50s of 0.65 μM and 0.6 μM in MTS and CPE cells, respectively. |
|
V76087 | HCoV-OC43-IN-1 | 2809363-81-1 | HCoV-OC43-IN-1 (Compound IV-16) is a coronavirus HCoV-OC43 inhibitor. |
|
V51994 | HeE1-2Tyr | 2245195-67-7 | HeE1-2Tyr is a pyridobenzothiazole, an inhibitor (blocker/antagonist) of flaviviral RNA-dependent RNA polymerase (RdRp). |
|
V76084 | Hispidulin 4'-O-β-D-glucopyranoside | 244285-12-9 | Hispidulin 4'-O-β-D-glucopyranosid is a naturally occurring compound with potential anti-COVID-19 protease inhibitor activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
